(Total Views: 347)
Posted On: 09/04/2019 9:53:08 AM
Post# of 153459
That is an interesting interpretation of the mono investigational trial that has or will be concluding soon.
As far as 525 mg dose for mono pivotal trial, I believe they will not do a single dose or random dose, but use the Receptor Occupancy Test to determine optimal dose for each individual.
EDIT: This is still odd to thank trial patients (whether HIV, TNBC, etc) in a NASH IND PR without specifically stating who.
As far as 525 mg dose for mono pivotal trial, I believe they will not do a single dose or random dose, but use the Receptor Occupancy Test to determine optimal dose for each individual.
EDIT: This is still odd to thank trial patients (whether HIV, TNBC, etc) in a NASH IND PR without specifically stating who.
(1)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼
